drugset / Trial / NCT04462965
Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study
RandomizedSequentialQuadruple-blindTreatment
Summary
A mucosal melanoma postoperative adjuvant treatment of multicenter, randomized, double-blind, placebo-controlled phase II study, evaluation of mucosal melanoma patients accept completely resected, Toripalima Combined with Temozolomide and Cisplatin postoperative adjuvant therapy efficacy and safety
Timeline
- Start
- 2020-05-30
- Primary completion
- 2024-11-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Background | Temozolomide | Small molecule | 200 mg/m2 | Oral |